EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges (Q36746340)

16 August 2017

1 reference

20 January 2021

EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges (English)

1 reference

gastrointestinal neoplasm

16 August 2017

1 reference

20 January 2021

1 reference

9 September 2020

cell adhesion molecule

1 reference

16 December 2020

M A Chaudry

1

1 reference

16 August 2017

K Sales

2

1 reference

16 August 2017

P Ruf

3

1 reference

16 August 2017

H Lindhofer

4

1 reference

16 August 2017

M C Winslet

5

1 reference

16 August 2017

language of work or name

English

0 references

publication date

27 February 2007

1 reference

British Journal of Cancer

16 August 2017

10 April 2007

5 references

3 April 2019

25 June 2019

15 December 2019

16 December 2020

20 January 2021

6 references

16 August 2017

3 April 2019

25 June 2019

15 December 2019

16 December 2020

20 January 2021

96

1 reference

16 August 2017

7

1 reference

16 August 2017

1013-1019

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603505

16 August 2017

0 references

cites work

Immunotherapy of malignant ascites with trifunctional antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

Frequent EpCam protein expression in human carcinomas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

MUC1 in carcinoma-host interactions

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

Anti-idiotype and recombinant antigen in immunotherapy of colorectal cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

Immunohistochemical studies of the distribution of a basolateral-membrane protein in intestinal epithelial cells (GZ1-Ag) in rats using monoclonal antibodies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

Biologic effects of gamma interferon pre-treatment followed by monoclonal antibody 17-1A administration in patients with gastrointestinal carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360124

Ep-CAM overexpression in breast cancer as a predictor of survival

5 September 2018

1 reference

12 December 2020

Rituximab as first-line systemic therapy for patients with low-grade lymphoma

1 reference

12 December 2020

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

1 reference

12 December 2020

In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment

1 reference

12 December 2020

Immunohistochemical localization and characterization of a protein from the basolateral membrane of rat small intestine epithelium using monoclonal antibody GZ-1

1 reference

12 December 2020

Influence of syngeneic (anti-idiotypic) antibody responses on biodistribution and tumour localisation of murine monoclonal antibodies and fragments

1 reference

12 December 2020

Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients

1 reference

12 December 2020

Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes

1 reference

12 December 2020

Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies

1 reference

12 December 2020

Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor

1 reference

12 December 2020

Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6603505

1 reference

16 August 2017

1 reference

16 August 2017

1 reference